Rosiglitazone Aggravates Nonalcoholic Fatty Pancreatic Disease in C57BL/6 Mice Fed High-Fat and High-Sucrose Diet
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: Evaluate the effect of fenofibrate, bezafibrate, and rosiglitazone on nonalcoholic fatty pancreatic disease and islet peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-beta immunostain in mice fed high-fat high-sucrose (HFHS) diet. METHODS: Two-month-old male mice were fed standard chow (n = 10) or HFHS chow (n = 40) for 6 weeks. Afterward, HFHS mice were grouped by treatment: untreated HFHS and HFHS treated with rosiglitazone (HFHS-Ro), fenofibrate (HFHS-Fe), or bezafibrate (HFHS-Bz). Medications were administered for 5 weeks. After treatment, the pancreas was removed and analyzed by morphometry, stereology, and immunohistochemistry. RESULTS: The HFHS-fed mice showed altered fasting glucose (+33%) and insulin (+138%); increased body (+20%) and pancreas (+28%) masses, pancreatic fat (+700%), islet hypertrophy (+38%); and decreased GLUT2 immunostain (-60%). Rosiglitazone reduced fasting glucose and insulin but induced weight gain. Fibrates impeded weight gain, but only bezafibrate prevented islet hypertrophy. The GLUT2 stain was improved in all treatments, and there were no alterations in PPAR-alpha. There were morphological signs of pancreatitis with fenofibrate, although there were no alterations in amylase and lipase. Rosiglitazone exacerbated pancreatic fat infiltration (+75% vs HFHS group), and bezafibrate increased PPAR-beta expression in pancreatic islets. CONCLUSIONS: Rosiglitazone is shown for the first time to exacerbate pancreatic fat infiltration; therefore, precaution has to be taken when rosiglitazone is prescribed to obese patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Braissant, O., Foufelle, F., Scotto, C., Dauça, M., & Wahli, W. (1996) · Endocrinology · doi:10.1210/endo.137.1.8536636 · Cited by 2,217
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827
The PPARs: From Orphan Receptors to Drug Discovery
Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816 · cited 1×
“The 3 PPAR isoforms (PPAR->, PPAR-A/C, and PPAR-F) are expressed in different tissues, each having various functions in lipoprotein metabolism and glucose homeostasis.(8,9) In the treatment of hyperlipidemia and type 2 diabetes, the significance of PPAR pathways in the management of metabolic disease is highlighted by…”
BackgroundA pilot study of pioglitazone treatment for nonalcoholic steatohepatitis
Promrat, K., Lutchman, G., Uwaifo, G. I., Freedman, R. J., Soza, A., Heller, T., Doo, E., Ghany, M., Premkumar, A., Park, Y., et al. (2004) · Hepatology · doi:10.1002/hep.20012 · Cited by 726
Cited by
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944
Fraulob, J. C., Ogg-Diamantino, R., Fernandes-Santos, C., Aguila, M. B., & Mandarim-de-Lacerda, C. A. (2010) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.09-83 · Cited by 448
Self-citationThe clinical significance of pancreatic steatosis
Smits, M. M., & van Geenen, E. J. M. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.4 · Cited by 325
Ludgero-Correia, A., Aguila, M. B., Mandarim-de-Lacerda, C. A., & Faria, T. S. (2012) · Nutrition · doi:10.1016/j.nut.2011.07.014 · Cited by 121
Fatty pancreas: A possible risk factor for pancreatic cancer in animals and humans
Takahashi, M., Hori, M., Ishigamori, R., Mutoh, M., Imai, T., & Nakagama, H. (2018) · Cancer Science · doi:10.1111/cas.13766 · Cited by 120
Metadata
- Authors
- Fernandes-Santos, C., Evangelista Carneiro, R., de Souza Mendonca, L., Barbosa Águila, M., & Alberto Mandarim-de-Lacerda, C.
- Venue
- Pancreas
- Published
- 2009-04
- Volume
- 38
- Issue
- 3
- Pages
- e80-e86
- ISSN
- 0885-3177 (ISSN-L)
- OpenAlex
- W1981277150
- Cited by
- 60
- References
- 5
- FWCI
- 1.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rosiglitazone Aggravates Nonalcoholic Fatty Pancreatic Disease in C57BL/6 Mice Fed High-Fat and High-Sucrose Diet. https://app.cochat.ai/papers/10.1097/mpa.0b013e3181987d9d
- The paper
- Fernandes-Santos, C., Evangelista Carneiro, R., de Souza Mendonca, L., Barbosa Águila, M., & Alberto Mandarim-de-Lacerda, C. (2009). Rosiglitazone Aggravates Nonalcoholic Fatty Pancreatic Disease in C57BL/6 Mice Fed High-Fat and High-Sucrose Diet. Pancreas. https://doi.org/10.1097/mpa.0b013e3181987d9d
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.